Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $98.1 million.

  • Niagen Bioscience's Liabilities and Shareholders Equity rose 7362.97% to $98.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.3 million, marking a year-over-year increase of 5449.86%. This contributed to the annual value of $68.3 million for FY2024, which is 2422.31% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Liabilities and Shareholders Equity is $98.1 million, which was up 7362.97% from $91.5 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Liabilities and Shareholders Equity peaked at $98.1 million during Q3 2025, and registered a low of $45.7 million during Q3 2022.
  • In the last 5 years, Niagen Bioscience's Liabilities and Shareholders Equity had a median value of $54.5 million in 2023 and averaged $61.3 million.
  • Per our database at Business Quant, Niagen Bioscience's Liabilities and Shareholders Equity tumbled by 2920.48% in 2022 and then skyrocketed by 7362.97% in 2025.
  • Over the past 5 years, Niagen Bioscience's Liabilities and Shareholders Equity (Quarter) stood at $57.8 million in 2021, then decreased by 6.54% to $54.1 million in 2022, then grew by 1.68% to $55.0 million in 2023, then rose by 24.22% to $68.3 million in 2024, then surged by 43.73% to $98.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $98.1 million in Q3 2025, compared to $91.5 million in Q2 2025 and $81.3 million in Q1 2025.